User menu

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.

Bibliographic reference Harrison, Claire N ; Mesa, Ruben A ; Kiladjian, Jean-Jacques ; Al-Ali, Haifa-Kathrin ; Gisslinger, Heinz ; et. al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.. In: British journal of haematology, Vol. 162, no.2, p. 229-39 (2013)
Permanent URL http://hdl.handle.net/2078.1/141289
  1. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., Haes J. C. J. M. d., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P. B., Schraub S., Sneeuw K., Sullivan M., Takeda F., The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, 10.1093/jnci/85.5.365
  2. Carter, Blood, 112, 828 (2008)
  3. Cervantes F, Passamonti F, Barosi G, Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders, 10.1038/leu.2008.72
  4. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J. T., Morra E., Vannucchi A. M., Mesa R. A., Demory J.-L., Barosi G., Rumi E., Tefferi A., New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, 10.1182/blood-2008-07-170449
  5. Harrison Claire, Kiladjian Jean-Jacques, Al-Ali Haifa Kathrin, Gisslinger Heinz, Waltzman Roger, Stalbovskaya Viktoriya, McQuitty Mari, Hunter Deborah S., Levy Richard, Knoops Laurent, Cervantes Francisco, Vannucchi Alessandro M., Barbui Tiziano, Barosi Giovanni, JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, 10.1056/nejmoa1110556
  6. Kvam Ann K., Fayers Peter, Wisloff Finn, What changes in health-related quality of life matter to multiple myeloma patients? A prospective study, 10.1111/j.1600-0609.2009.01404.x
  7. Mesa Ruben A., Verstovsek Srdan, Cervantes Francisco, Barosi Giovanni, Reilly John T., Dupriez Brigitte, Levine Ross, Le Bousse-Kerdiles Marie-Caroline, Wadleigh Martha, Campbell Peter J., Silver Richard T., Vannucchi Alessandro M., Deeg H. Joachim, Gisslinger Heinz, Thomas Deborah, Odenike Olatoyosi, Solberg Lawrence A., Gotlib Jason, Hexner Elizabeth, Nimer Stephen D., Kantarjian Hagop, Orazi Attilio, Vardiman James W., Thiele Juergen, Tefferi Ayalew, Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT), 10.1016/j.leukres.2006.12.002
  8. Mesa Ruben A., Niblack Joyce, Wadleigh Martha, Verstovsek Srdan, Camoriano John, Barnes Sunni, Tan Angelina D., Atherton Pamela J., Sloan Jeff A., Tefferi Ayalew, The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) : An international internet-based survey of 1179 MPD patients, 10.1002/cncr.22365
  9. Mesa, Blood, 118, 765 (2011)
  10. Oken Martin M., Creech Richard H., Tormey Douglass C., Horton John, Davis Thomas E., McFadden Eleanor T., Carbone Paul P., Toxicity and response criteria of the Eastern Cooperative Oncology Group : , 10.1097/00000421-198212000-00014
  11. Oliva E. N., Nobile F., Alimena G., Ronco F., Specchia G., Impera S., Breccia M., Vincelli I., Carmosino I., Guglielmo P., Pastore D., Alati C., Latagliata R., Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians, 10.3324/haematol.2010.036715
  12. Osoba D, Rodrigues G, Myles J, Zee B, Pater J, Interpreting the significance of changes in health-related quality-of-life scores., 10.1200/jco.1998.16.1.139
  13. Passamonti F., Cervantes F., Vannucchi A. M., Morra E., Rumi E., Pereira A., Guglielmelli P., Pungolino E., Caramella M., Maffioli M., Pascutto C., Lazzarino M., Cazzola M., Tefferi A., A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment), 10.1182/blood-2009-09-245837
  14. Verstovsek Srdan, Mesa Ruben A., Gotlib Jason, Levy Richard S., Gupta Vikas, DiPersio John F., Catalano John V., Deininger Michael, Miller Carole, Silver Richard T., Talpaz Moshe, Winton Elliott F., Harvey Jimmie H., Arcasoy Murat O., Hexner Elizabeth, Lyons Roger M., Paquette Ronald, Raza Azra, Vaddi Kris, Erickson-Viitanen Susan, Koumenis Iphigenia L., Sun William, Sandor Victor, Kantarjian Hagop M., A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, 10.1056/nejmoa1110557
  15. Wang X. S., Clinical Factors Associated With Cancer-Related Fatigue in Patients Being Treated for Leukemia and Non-Hodgkin's Lymphoma, 10.1200/jco.20.5.1319
  16. Webster Kimberly, Cella David, Yost Kathleen, 10.1186/1477-7525-1-79